Patent details

EP1658848 Title: Formulations comprising ecteinascidin and a disaccharide

Basic Information

Publication number:
EP1658848
PCT Application Number:
Type:
European Patent Granted for LU
Legal Status:
Expired
Application number:
EP050773332
PCT Publication Number:
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
Formulations comprising ecteinascidin and a disaccharide
French Title of Invention:
Compositions contenant d'ecteinascidin et undisaccharide
German Title of Invention:
Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
SPC Number:

Dates

Filing date:
12/10/2005
Grant date:
01/08/2007
EP Publication Date:
01/08/2007
PCT Publication Date:
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
24/05/2006
EP B1 Publication Date:
01/08/2007
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
12/10/2025
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
12/10/2005
 
 

Name:
Pharma Mar S.A. Sociedad Unipersonal
Address:
Polígono Industrial La Mina Avda. de los Reyes, 1 Colmenar, 28770 Madrid, Spain (ES)

Agent

Name:
MARKS & CLERK LLP
From:
29/08/2007
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
Tobio Barreira Maria
Address:
Spain (ES)

2

Name:
Nuijen Bastiaan
Address:
Netherlands (NL)

3

Name:
Beijnen Jacob Hendrik
Address:
Netherlands (NL)

4

Name:
Calvo Salve Pilar
Address:
Spain (ES)

Priority

Priority Number:
623813 P
Priority Date:
29/10/2004
Priority Country:
United States (US)

Classification

Main IPC Class:
A61K 31/4995;

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
28/10/2024
Last Annual Fee Paid Number:
20
Last Annual Fee Paid Amount:
300 Euro
Payer:
Computer Packages INC
Filing date Document type Number of pages
12/08/2022 Request For Change 1
02/09/2022 Outgoing Correspondence 56